イスラエルで最高のルテチウム177療法医師 - トップ5名の医師

オフェル・メリムスキー教授は、骨腫瘍・軟部腫瘍・中皮腫・肺癌・肝臓および肺への転移性病変を専門とする著名な腫瘍内科医です。スラスキー医療センター（イヒロフ、テルアビブ）の骨格・軟部腫瘍科の科長を務め、イスラエル臨床腫瘍医協会の会長を兼任しています。

主な専門領域と患者様へのメリット：

• 豊富な臨床経験と国際的な診療実績として、米国・フランス・イスラエルでの研修歴およびエルサレム大学での教育活動が挙げられ、高精度の先進的診断・治療法の提供が可能です。
• 腫瘍科的治療法には、肉腫・中皮腫・骨格および軟部腫瘍の治療のほか、放射線療法および小線源治療が含まれます。希少かつ難治性の腫瘍疾患に対しても、患者様は包括的な治療を受けることができます。
• 権威ある学術誌への多数の論文掲載実績として、New England Journal of Medicine（N Engl J Med）、Annals of Oncology、および欧州臨床腫瘍学会（European Society for Medical Oncology、ESMO）関連誌への発表があり、患者様が最新かつエビデンスに基づいた治療法を受けられることを保証しています。
• 国際学術団体への加盟として、Society of Oncologists and Radiotherapists Israel、ASCO、EMSOS、CTOSへの所属が、その高い専門性を証明するとともに、最新の治療プロトコルへのアクセスを可能にしています。
• オンライン診療を通じた遠隔診察・助言の提供が可能であり、世界どこからでも専門家による医療支援を受けることができます。

患者様はメリムスキー教授の深い腫瘍学的知識、個別化された治療計画の立案能力、そして細やかな対応を高く評価しており、治療の全過程を通じて安心感と信頼感が得られると好評です。

アリ・ラファエル教授――テルアビブ・スラスキー医療センター（イキロフ、テルアビブ）トランスレーショナル腫瘍学部門長および臨床がん研究部門研究員。患者一人ひとりのニーズに寄り添う個別対応のアプローチが高く評価されています。

資格および患者への貢献：

• 腫瘍科デイホスピタルを統括し、国家ゲノム医療プロジェクトを主導。最先端の研究へのアクセスを提供しています。

• 主任副研究者および主任研究者として、腫瘍内mRNA投与やウイルス製剤を含むフェーズI〜IIIの多数の臨床試験に携わってきました。患者は革新的な治療法への参加機会を得られます。

• 米国および英国における国際的な臨床経験を有し、世界水準の治療基準と先進的なプロトコルの適用を保証しています。

• 国際学術団体の会員（ESMO、IASLC、ISLB、ISCORT、Israeli Medical Association）。最新の治療基準を活用し、国際的な研究に参画しています。

• 　ICH GCP R2、Israeli MOH Guidelinesをはじめ、インフォームドコンセント、副作用管理および患者安全に関する最新課程を含む国際臨床実践基準に基づき、定期的に専門知識の更新および研修を実施しています。

ラファエル教授は、精密な治療レジメンの選択、革新的手法の導入、そして細やかな患者対応により高い信頼を得ており、治療のすべての段階において患者が安心して療養に臨める環境を提供しています。

Dr. Irina Stepfansky is an oncologist and internal medicine specialist at Sourasky Medical Center. She has more than 25 years of clinical experience. Since 2015, she has directed the Oncology Hospitalization department. Dr. Stepfansky earned her medical degree from Grodno University in Belarus. She completed advanced oncology training at Tel Aviv Medical Center.

Dr. Stepfansky has been licensed in Israel since 2000. She has led and participated in many phase I-III oncology clinical trials. Her work has helped improve cancer care and patient outcomes. She is recognized for her expertise in both internal medicine and oncology. Dr. Stepfansky has a strong record in research and clinical leadership.

Coping with gastrointestinal and lung cancer without chemotherapy. Specialists at the Tel Aviv Sourasky Clinic (Ichilov) use an ultra-modern innovative method to combat neuroendocrine tumors. It is based on radionuclide therapy with the radioisotope Lutetium 177 (Lutetium-177). This innovation is a real breakthrough in oncotherapy, because in recent decades the number of cases of this type of cancer has been rapidly growing.

This method is completely new in the world. Today it exists only in Israel, Germany and Sweden.

Its essence is in the use of a new radiopharmaceutical - Lutetium 177 PRRT. The drug is administered intravenously at intervals of 7-8 weeks. With the help of Lutetium, cancer cells are destroyed selectively, without affecting healthy tissues of the body. That is, this method of treatment can literally be called "local radiation therapy". In addition, the drug does not have a toxic effect on the bone marrow and kidneys, destroying the tumor from the inside.

In addition, the use of this method allows patients to avoid severe side effects of chemotherapy, such as vomiting, nausea, pain, alopecia, weakness. It is also important that the treatment is carried out by a special group of medical specialists. Among them: leading doctors, nurses and medical physicists!

All of them work under the supervision of Dr. Inna Ospovat, a leading specialist in the nuclear therapy department at the Ichilov Clinic.

Education

2000-1994 Faculty of Medicine in Vitebsk, Belarus.

Specialization

2003 - 2011 - specialization in oncology and radiation therapy at the Hadassah University Hospital in Jerusalem.

Recognized experience

Oncology and radiation therapy

Additional education

2015 - PMH University Hospital (Totonto) Childhood irradiation and head and neck tumors

Attending conferences

About 10 presentations at medical conferences

Trade union membership

• Israel Society of Clinical Oncology and Radiotherapy ISCORT
• American Association of Radiation Therapy ASTRO
• Israel Head and Neck Oncology Association
• Areas of special interest and activities
• Radiation therapy in children
• Radiobiological treatment PRBT
• Radiation therapy for gastrointestinal tumors
• Treatment of head and neck tumors and skin tumors

EDUCATION AND ADVANCED TRAINING COURSES

• 1989 - received higher medical education at the Hebrew University;
• 1995 - completed residency in internal medicine and gastroenterology at the Hadassah University Hospital.
• 2001 - 2002 - Internship with Professor Scott Friedman in the Department of Liver Diseases at Sinai School of Medicine in New York.

Today, Professor Rifaat Safadi is an outstanding specialist in the field of liver disease treatment, a member of the committee for the development of the somatic cell transplant center and the head of the liver disease unit at Hadassah Medical Center. The professor is a member of several international associations for the study of the liver and is the author of numerous articles in his specialty. Professor Safadi is a member of the editorial board of the scientific medical journal Clinical Science.

Rifaat Safadi is a laureate of many scientific awards. In particular, he has been repeatedly awarded the Hadassah Prize for studying the process of immune modulation of liver fibrosis using mRNA. For achievements in the same field, the professor received the Sharon Donsky and the Israeli Association of Gastroenterology and Hepatology awards.